BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Aflibercept: trial readouts and FDA decisions

3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 10 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Kyowa Kirin Co., Ltd., AbbVie, EyePoint Pharmaceuticals, Inc., Qilu Pharmaceutical Co., Ltd., Adverum Biotechnologies, Inc., Ocular Therapeutix, Inc., Beijing Anlong Biopharmaceutical Co., Ltd., Kodiak Sciences Inc. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3Qilu Pharmaceutical Co., Ltd.NCT07489586 A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular DegenerationNeovascular Age-Related Macular Degeneration (nAMD)not yet recruiting356
2026-12-22 est.P3Adverum Biotechnologies, Inc.NCT06856577 Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationNeovascular Age-Related Macular Degeneration (nAMD); Wet AMDactive not recruiting311
2027-01-08 est.P3Ocular Therapeutix, Inc. OCULNCT06495918 Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationNeovascular Age-related Macular Degenerationactive not recruiting825

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-31 est.P2Kyowa Kirin Co., Ltd.NCT06116916 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaDiabetic Macular Edema (DME)active not recruiting185
2026-10 est.P3AbbVie ABBVNCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDAMD; nAMD; Wet Age-related Macular Degeneration; wAMD; WetAMD; CNVactive not recruiting735
2026-09-30 est.P2Beijing Anlong Biopharmaceutical Co., Ltd.NCT06839339 Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMDWet Age-related Macular Degeneration (wAMD)not yet recruiting40
2026-09-09P3EyePoint Pharmaceuticals, Inc. EYPTNCT06683742 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Wet Age Related Macular Degeneration; wAMDactive not recruiting400
2026-09-02P3Kodiak Sciences Inc KODNCT06556368 A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-reWet Age-related Macular Degenerationactive not recruiting667
2026-09 est.P3Salutaris Medical Devices, Inc.NCT05251636 Adjunct Episcleral Brachytherapy for PCVAge-Related Macular Degeneration; Polypoid Choroidal Vasculopathynot yet recruiting159
2026-07-13P3EyePoint Pharmaceuticals, Inc. EYPTNCT06668064 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56Wet Age Related Macular Degeneration; wAMDactive not recruiting400
2026-06-18P2AbbVie ABBVNCT04567550 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Diabetic Retinopathy (DR); Center-Involved Diabetic Macular Edema (CI-DME)completed139
2026-06-03P2Kyowa Kirin Co., Ltd.NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationNeovascular Age-Related Macular Degeneration (nAMD)completed170
2026-06 est.P3RemeGen Co., Ltd.NCT05885503 Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular EdemaDiabetic Macular Edemaunknown316

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.